Current Vaccine Recomendations
10 October 2025
The AIVC met in October 2025 and recommended that the following viruses be used for influenza vaccines in the 2026 Southern Hemisphere influenza season:
Egg-based vaccines:
Cell culture-, recombinant protein- or nucleic acid-based vaccines
The continued absence of confirmed detection of naturally occurring B/Yamagata lineage viruses after March 2020 is indicative of a very low risk of infection by B/Yamagata lineage viruses. Consistent with the World Health Organization (WHO) recommendations since September 2023, it remains the opinion of the WHO influenza vaccine composition advisory committee that the inclusion of a B/Yamagata lineage antigen is no longer warranted. There will no longer be updated recommendations for the B/Yamagata lineage component. This position is supported by the AIVC. Further, the AIVC supports the use of trivalent influenza virus vaccines within Australia for the 2026 influenza season.
See the TGA website for further information
26 September 2025
The WHO recommends that trivalent vaccines for use in the 2026 Southern Hemisphere season contain the following:
Egg-based vaccines:
Cell culture-, recombinant protein- or nucleic acid-based vaccines
Consistent with the four previous WHO recommendations since September 2023, it remains the opinion of the WHO influenza vaccine composition advisory committee that the inclusion of a B/Yamagata lineage antigen is no longer warranted.
28 Febuary 2025
The WHO recommends that trivalent vaccines for use in the 2025-2026 Northern Hemisphere season contain the following:
Egg based vaccines:
Cell or recombinant based vaccines:
For quadrivalent egg- or cell culture-based or recombinant vaccines for use in the 2025-2026 northern hemisphere influenza season: While the B/Yamagata lineage vaccine component should be excluded as it is no longer warranted, where quadrivalent vaccines are still in use, the B/Yamagata lineage component remains unchanged:
Egg-, cell- or recombinant-based Vaccines
16 October 2024
The AIVC met in October 2024 and recommended that the following viruses be used for influenza vaccines in the 2025 Southern Hemisphere influenza season:
Egg based trivalent influenza vaccines:
Cell-based trivalent influenza vaccines:
The recommendation for the B/Yamagata lineage component of quadrivalent influenza vaccines remains unchanged from previous recommendations:
See the TGA website for further information
27 September 2024
The WHO recommends that trivalent vaccines for use in the 2025 Southern Hemisphere season contain the following:
Egg-based vaccines:
Cell culture-, recombinant protein- or nucleic acid-based vaccines
The recommendation for the B/Yamagata lineage component of quadrivalent influenza vaccines remains unchanged from previous recommendations